Overview

Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function in T2DM Patients With Mild Cognitive Impairment: a Multicenter, Randomized, Parallel Controlled Clinical Trial

Status:
Recruiting

Trial end date:
2027-06-01

Target enrollment:

Participant gender:

Summary

This is a prospective, randomized, open label, parallel, 12-month study to explore and evaluate the therapeutic effects of Liraglutide, Empagliflozin and Linagliptin on the cognitive function, olfactory function, and odor-induced brain activation in T2DM patients with mild cognitive impairment(MCI).

Phase:

N/A

Details

Lead Sponsor:

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Collaborators:

The First Affiliated Hospital with Nanjing Medical University
Wuxi People's Hospital

Treatments:

Empagliflozin
Linagliptin
Liraglutide
Metformin